Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.

Breast cancer research and treatment - 1 Sept 2021

Liu Xinhua, Qiu Rongfang, Xu Min, Meng Miaomiao, Zhao Siyu, Ji Jiansong, Yang Yang

Abstract excerpt

PURPOSE: Epigenetic regulation plays critical roles in cancer progression, and high-frequency mutations or expression variations in epigenetic regulators have been frequently observed in tumorigenesis, serving as biomarkers and targets for cancer therapy. Here, we aimed to explore the function of epigenetic regulators in breast cancer. METHODS: The mutational landscape of epigenetic regulators in breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 34240274
DOI: 10.1007/s10549-021-06325-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.PMID 34240274Read ↗

KMT2C and KMT2D aberrations in breast cancer.Semantic proximity Read ↗

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancersSemantic proximity Read ↗

Epigenetic mutational landscape in breast cancer: role of the histone methyltransferase gene KMT2D in triple negative tumorsSemantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

KMT2C is Potential Prognostic Biomarker and its Immune Regulating Roles in Pan-Cancer: A Comprehensive AnalysisSemantic proximity Read ↗

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.Semantic proximity Read ↗

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.Semantic proximity Read ↗

Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.Semantic proximity Read ↗

A Pan-Cancer Study of KMT2 Family as Therapeutic Targets in CancerSemantic proximity Read ↗

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironmentsSemantic proximity Read ↗

Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer.Semantic proximity Read ↗

The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.